Tango Therapeutics, Inc. — Director's Dealing 2021

Aug 13, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Tango Therapeutics, Inc. (TNGX)
CIK: 0001819133
Period of Report: 2021-08-10

Reporting Person: Peters Malte (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.383	2028-09-14	Common Stock (118901)		Direct

Footnotes

F1: This option shall vest and become exercisable in equally quarterly installments over a period of 48 months from September 11, 2018.